Century Therapeutics, Inc. (IPSC) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -109.79M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-109.79M | (m) |
| 2026-03-31 | (m) | $-107.78M | (m) |
| 2025-12-31 | (m) | $-9.58M | (m) |
| 2025-09-30 | (m) | $-26.48M | (m) |
| 2025-06-30 | (m) | $-23.28M | (m) |
| 2025-03-31 | (m) | $-21.94M | (m) |
| 2024-12-31 | (m) | $-126.57M | (m) |
| 2024-09-30 | (m) | $-129.89M | (m) |
| 2024-06-30 | (m) | $-131.39M | (m) |
| 2024-03-31 | (m) | $-133.47M | (m) |
| 2023-12-31 | (m) | $-136.67M | (m) |
| 2023-09-30 | (m) | $-128.96M | (m) |
| 2023-06-30 | (m) | $-126.99M | (m) |
| 2023-03-31 | (m) | $-124.68M | (m) |
| 2022-12-31 | (m) | $-130.93M | (m) |
| 2022-09-30 | (m) | $-127.44M | (m) |
| 2022-06-30 | (m) | $-122.70M | (m) |
| 2022-03-31 | (m) | $-114.99M | (m) |
| 2021-12-31 | (m) | $-95.82M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-53.58M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |